- Home
- SNTI vs GROW Comparison
SNTI vs GROW Comparison
Compare SNTI & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- GROW
- Stock Information
- Founded
- SNTI 2016
- GROW 1968
- Country
- SNTI United States
- GROW United States
- Employees
- SNTI N/A
- GROW 26
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- GROW Investment Managers
- Sector
- SNTI Health Care
- GROW Finance
- Exchange
- SNTI Nasdaq
- GROW Nasdaq
- Market Cap
- SNTI 39.6M
- GROW 32.2M
- IPO Year
- SNTI N/A
- GROW N/A
- Fundamental
- Price
- SNTI $1.56
- GROW $2.43
- Analyst Decision
- SNTI Strong Buy
- GROW
- Analyst Count
- SNTI 2
- GROW 0
- Target Price
- SNTI $8.50
- GROW N/A
- AVG Volume (30 Days)
- SNTI 107.2K
- GROW 21.6K
- Earning Date
- SNTI 08-07-2025
- GROW 09-09-2025
- Dividend Yield
- SNTI N/A
- GROW 3.70%
- EPS Growth
- SNTI N/A
- GROW N/A
- EPS
- SNTI N/A
- GROW 0.01
- Revenue
- SNTI N/A
- GROW $8,932,000.00
- Revenue This Year
- SNTI N/A
- GROW N/A
- Revenue Next Year
- SNTI $150.00
- GROW N/A
- P/E Ratio
- SNTI N/A
- GROW $232.40
- Revenue Growth
- SNTI N/A
- GROW N/A
- 52 Week Low
- SNTI $1.46
- GROW $2.02
- 52 Week High
- SNTI $16.94
- GROW $2.68
- Technical
- Relative Strength Index (RSI)
- SNTI 37.24
- GROW 49.24
- Support Level
- SNTI $1.52
- GROW $2.38
- Resistance Level
- SNTI $1.65
- GROW $2.49
- Average True Range (ATR)
- SNTI 0.10
- GROW 0.07
- MACD
- SNTI 0.03
- GROW -0.00
- Stochastic Oscillator
- SNTI 50.00
- GROW 42.86
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.